Eric Feldman
Keine laufenden Positionen mehr
Profil
Eric Feldman formerly worked at Seagen Inc., as Senior Medical Director from 2014 to 2017, NewYork-Presbyterian Hospital, as Director-Hematological Malignancies Service, GlycoMimetics, Inc., as Vice President-Clinical Development from 2019 to 2021, and Amphivena Therapeutics, Inc., as Chief Medical Officer from 2018 to 2019.
Dr. Feldman received his undergraduate degree from Tulane University (Louisiana) and undergraduate degree from New York Medical College.
Ehemalige bekannte Positionen von Eric Feldman
| Unternehmen | Position | Ende |
|---|---|---|
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01.04.2019 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2017 |
NewYork-Presbyterian Hospital
 NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| GLYCOMIMETICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Eric Feldman
| Tulane University (Louisiana) | Undergraduate Degree |
| New York Medical College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
NewYork-Presbyterian Hospital
NewYork-Presbyterian Hospital Hospital/Nursing ManagementHealth Services NewYork-Presbyterian Hospital offers healthcare services. Its services include surgery, corporate health, nephrology, dermatology, cardiology, hepatology, vascular care, emergency care, and ambulatory care. The company was founded in 1771 and is headquartered in New York, NY. | Health Services |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
